title: Pharmacokinetic analysis of plasma curves obtained after i.v. injection of the PET radioligand [11C] raclopride provides a likely explanation for rapid radioligand metabolism.
abstract: Positron emission tomography (PET) is an imaging technique that provides direct measurements of receptor binding in neurons. The present study was performed to find reasons for the common observation of rapid metabolism of receptor radioligands during time of a brain PET scan. To this aim, the 1-h phase during which imaging-data are acquired was evaluated by using a pharmacokinetic approach. The values of half-lives, volumes of distribution, and dilution calculated for a set of metabolite corrected plasma curves of D2-receptor radioligand [(11)C]raclopride (PETc) during 50 min after radioligand injection in tracer dose were compared with the reference values obtained from a set of plasma curves (REFc) during 30 h after i.v. infusion of unlabelled raclopride in pharmacological doses. We found that the half-life of PETc correspond to the distribution half-life of REFc. Accordingly, the distribution volume during the terminal phase of PETc (13.6 ± 10.8 L) was significantly lower than that during the terminal phase (82.2 ± 30.5 L) and at steady state (59.4 ± 20 L) for REFc, and the dilution of raclopride in body for PETc at 50 min was 38 L, whereas it was 1015 L for REFc at 30 h. The [(11)C]raclopride in plasma at 50 min was higher (10% of dose) than the value for unlabelled raclopride at 30 h (4%). We concluded that the kinetic behavior of the radiolabelled drug [(11)C]raclopride during the 1 h time of a PET corresponds to the distribution phase. The high percentage of [(11)C]raclopride in plasma during this phase is a likely reason for the observed rapid radioligand metabolism.
authors.affiliation: Nuclear Medicine Unit, Ospedale Misericordia e Dolce, USL4 Prato, Italy. ssestini@usl4.toscana.it
authors.forename: Stelvio
authors.initials: S
authors.lastname: Sestini
authors.forename: Christer
authors.initials: C
authors.lastname: Halldin
authors.forename: Luigi
authors.initials: L
authors.lastname: Mansi
authors.forename: Antonio
authors.initials: A
authors.lastname: Castagnoli
authors.forename: Lars
authors.initials: L
authors.lastname: Farde
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism; D016022:Case-Control Studies; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D005260:Female; D006207:Half-Life; D006801:Humans; D008024:Ligands; D008297:Male; D049268:Positron-Emission Tomography; D020891:Raclopride / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D012559:Schizophrenia / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D008024:Ligands; D019275:Radiopharmaceuticals; D017448:Receptors, Dopamine D2; D020891:Raclopride